Adaptive Biotechnologies ... (ADPT)

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to...

Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6...

Adaptive (ADPT) Q2 Revenue Surges 36%

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Chad M. Robins - Co-Founder, CEO & Chairman Karina Calzadilla - Vice...

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key m...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t...